因美纳股价近期承压，多重因素叠加致股价创阶段新低

Company Performance - The latest financial report for Illumina shows Q3 2025 revenue of $1.083 billion, a year-on-year growth of only 0.28%, and a net profit of $150 million, down 78.72% year-on-year [1] - Despite meeting revenue expectations for Q3 2025, the company reported a 30.7% decline in revenue from the Chinese market due to instrument export restrictions, impacting overall growth [1] - On February 9, 2026, JPMorgan downgraded Illumina's target price from $130 to $120, maintaining a "neutral" rating, reflecting cautious market sentiment regarding its short-term growth potential [1] Industry Policy and Environment - The life sciences sector, to which Illumina belongs, has seen a decline of 2.58% over the past five days, while the Nasdaq index fell by 1.57% [2] - Uncertainties in the Chinese market have been highlighted, with a 54% decline in instrument business attributed to policy restrictions, despite some pressure relief from localized production [2] Market Dynamics - On February 6, 2026, Illumina experienced a significant drop of 10.40% in stock price, with a trading volume of $537 million and a turnover rate of 2.91%, indicating concentrated selling pressure [3] - Institutional holdings have shown a shift, with the proportion of sell or reduce ratings rising to 16% in February from 18% in January, as some investors reduce positions due to slowing profit growth [3] Industry and Risk Analysis - The sequencing industry is facing intensified competition, particularly with breakthroughs in low-cost sequencing technologies that may pressure long-term profit margins, despite the NovaSeq X platform contributing significantly to high-throughput revenue [4] - Illumina's declining stock price is attributed to a combination of slowing performance growth, industry volatility, macro liquidity concerns, and regional risks [4]